What is Foresight Diagnostics?
Foresight Diagnostics is at the forefront of cancer diagnostics, specializing in a novel liquid biopsy testing platform designed for the measurement of minimal residual disease (MRD). This platform boasts a detection limit below 0.0001%, offering unparalleled sensitivity for a wide range of cancers. By providing physicians and biopharmaceutical companies with actionable insights, Foresight Diagnostics aims to enable more personalized and effective treatment strategies for patients, marking a significant step forward in precision oncology.
How much funding has Foresight Diagnostics raised?
Foresight Diagnostics has raised a total of $104.3M across 3 funding rounds:
Series A
$12.5M
Series B
$58.8M
Series B
$33M
Series A (2021): $12.5M with participation from Pear Ventures, Civilization Ventures, and Bluebird Ventures
Series B (2023): $58.8M led by Foresite Capital, Pear Ventures, and Bluebird Ventures
Series B (2024): $33M supported by Civilization Ventures, Bluebird Ventures, Stanford University, Pear, Agent Capital, and Foresite Capital
Key Investors in Foresight Diagnostics
Civilization Ventures
Civilization Ventures is a venture capital firm that invests in innovative companies within the health tech and biopharma sectors, focusing on preventative, personalized, and regenerative healthcare solutions. Since its inception in 2017, the firm has managed over $200 million in capital and partnered with more than 70 companies, supporting founders through a unique Fellowship program and a vast network of experienced executives. The firm has a strong track record, with 75 investments, 17 exits, and 3 unicorns in just 7 years. Their portfolio includes notable companies like Rocket Pharma and Omada Health, which are pioneering advancements in genomics, diagnostics, and digital health.
Bluebird Ventures
We are committed to building a network of the best partners to add value to Bluebird Ventures projects. We work with profitable partnering to delight customers with engaging and useful products. If you'd like to get involved please contact us.
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data. The firm targets breakthrough opportunities at the intersection of technology and biotechnology, employing a data science-driven investment approach. Their mission is to address significant unmet needs in healthcare by funding visionary businesses at various stages of their development. Foresite Capital aims to support innovators who are changing the landscape of healthcare through strategic partnerships and deep industry expertise.
What's next for Foresight Diagnostics?
With the recent influx of major strategic investment, Foresight Diagnostics is poised for significant expansion. The company's focus will likely be on scaling its operations, further refining its proprietary MRD detection technology, and forging strategic partnerships within the biopharmaceutical industry. This capital injection signals strong investor confidence in Foresight Diagnostics' potential to revolutionize cancer monitoring and treatment, positioning it for substantial growth and impact in the healthcare sector.
See full Foresight Diagnostics company page
